Antitrust is not usually a matter of life and death, but administrative law judge D Michael Chappell is going to hear otherwise this week. Starting today, Federal Trade Commission staff will square off with Illumina over the DNA-sequencing company’s completed acquisition of Grail, which is developing an innovative cancer-screening test. Both the government and the merging parties are expected to argue that their opponent is trying to obstruct this life-saving technology.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Read more here: Source link